Plasminogen activator system and its clinical significance in patients with a malignant disease;Plazminogen aktivátor systém a jeho klinický význam u pacientů s nádorovým onemocně ním

Klinicka Onkologie

Volumn 24, Issue 6, 2011, Pages 418-423

  Halámková, Jana ^a   Kiss, I ^a   Tomasek J ^a   Pavlovsky Z ^b   Cech Z ^c   Tucek S ^a   Hanakova L ^c   Moulis, M ^b   Penka, M ^c  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

PAI 1; PAI 2; Plasminogen activators; U PA; U PA receptor

Indexed keywords

CYTOKINE; ELASTASE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEASE NEXIN; PROTEIN KINASE B; STAT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ANGIOGENESIS; APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL DEATH; CELL FUNCTION; CELL MIGRATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; INTRACELLULAR SIGNALING; NEOPLASM; PLASMINOGEN ACTIVATION; REVIEW; SMOOTH MUSCLE FIBER;

FIBRINOLYSIS; HUMANS; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84455171615     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Brummel-Ziedins K, Orfeo T, Swords Jenny N et al. Blood coagulation and fibrinolysis. In: Greer JP, Foerster J, Rodgers JM et al. (eds). Wintrobe's Clinical Hematology. 12th ed. Baltimore: Lippincott Wiliams & Wilkins 2009: 528-619.
2. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target therapy. Thromb Haemost 1997; 78: 285-296. (Pubitemid 27289256)
3. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10(1): 39-49. (Pubitemid 38072742)
4. Pyke C, Kristensen P, Ralfkiaer E et al. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in tumor stroma. Cancer Res 1991; 51(15): 4067-4071.
5. Fay WP, Shapiro AD, Shih JL et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327(24): 1729-1733.
6. Carmeliet P, Stassen JM, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effect on haemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92(6): 2756-2760. (Pubitemid 24006541)
7. Hill SA, Shaughnessy SG, Joshua P et al. Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocyte cell line. Blood 1996, 87(12): 5061-5073. (Pubitemid 26189847)
8. Stefansson S, Peticlerc E, Wong MK et al. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276(11): 8135-8141.
9. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383(6599): 441-443. (Pubitemid 26330833)
10. Ganesh S, Sier CF, Heerding MM et al. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344(8919): 401-402. (Pubitemid 24248215)
11. Verspaget HW, Sier CF, Ganesh S et al. Prognostic value of plasminogen activators and theirs inhibitors in colorectal cancer. Eur J Cancer 1995; 31A(7-8): 1105-1109.
12. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49(1-3): 117-137. (Pubitemid 26181742)
13. Resnati M, Guttinger M, Valcamonica S et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15(7): 1572-1582. (Pubitemid 26112379)
14. Busso N, Masur SK, Lazega D et al. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epitelial cells. J Cell Biol 1994; 126(1): 259-270. (Pubitemid 24214945)
15. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273(14): 8502-8507. (Pubitemid 28168915)
16. Dumler I, Weis A, Mayboroda OA et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273(1): 315-321. (Pubitemid 28042211)
17. Durand MK, Bødker JS, Christensen A et al. Plasminogen activator inhibitor-1 and tumour growth, invasion and metastasis. Tromb Haemost 2004; 91 (3): 439-449.
18. Prager GW, Breuss JM, Steurer S et al. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004, 94(12): 1562-1570. (Pubitemid 38856963)
19. Jänicke F, Schmitt M, Ulm K et al. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 2(8670): 1049. (Pubitemid 19257967)
20. Duffy MJ, O'Grady P, Devaney D et al. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62(3): 531-533.
21. Jänicke F, Schmitt M, Haftner R et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78 (Pubitemid 20270731)
22. Duggan C, Maguire T, McDermott E et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995; 61(5): 597-600.
23. Foekens JA, Buessecker F, Peters HA et al. Plasminogen activator inhibitor 2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55(7): 1423-1427.
24. Foekens JA, Look MR Peters HA et al. Urokinase-typ plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87(10): 751-756.
25. Look MP, van Putten WL, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94(2): 116-128. (Pubitemid 34121291)
26. Kuhn W, Pache L, SchmalfeldT B et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994, 55(1): 401-409.
27. Fredstorp-Lidebring M, Bendahl PO, Brünner N et al. Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer 2001; 37(18): 2339-2348. (Pubitemid 33097469)
28. Kobayashi H, Fujishiro S, Terao T et al. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of uterus. Cancer Res 1994; 54(24): 6539-6548.
29. Gleeson N, Gonsalves R, Bonnar J et al. Uterine fibrinolytic enzymes in endometrial cancer. Eur J Gynaecol Oncol 1993; 14(5): 369-373. (Pubitemid 23293585)
30. Hasui Y, Marutsuka K, Asada Y et al. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996; 47(1): 34-37. (Pubitemid 26038300)
31. Hofmann R, Lehmer A, Buresch M et al. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996; 78(3): 487-492. (Pubitemid 26250535)
32. Ahmad A, Kong D, Sarkar SH et al. Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 2009; 107(3): 516-527.
33. Xue A, Scarlett CJ, Jackson CJ et al. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008; 36(2): 160-167.
34. Nomiya T, Nemoto K, Miyachi H et al. Significance of plasminogen- activation system in the formation of macroscopic types and invasion in esophageal carcinoma. Anticancer Res 2002; 22(5): 2913-2916 (Pubitemid 36069334)
35. Kaneko T, Konno H, Baba M et al. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003; 94(1): 43-49. (Pubitemid 36575857)
36. Hundsdorfer B, Zeilhofer HF, Bock KP et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Craniomaxillofac Surg 2005; 33(3): 191-196. (Pubitemid 40614180)
37. Hsu DW, Efird JT, Hedley-Whyte ET et al. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995; 147(1): 114-123.
38. Pappot H, Pedersen AN, Brunner N et al. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer 2006; 51(2): 193-200. (Pubitemid 43144362)
39. Choong PF, Fernö M, Akerman M et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996; 69(4): 268-272. (Pubitemid 26298289)
40. Morii T, Yabe H, Morioka H et al. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. Anticancer Res 2000; 20(5A): 3031-3036
41. Stephens RW, Nielsen HJ, Christensen IJ et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91(10): 869-874. (Pubitemid 29252303)
42. Ganesh S, Sier CF, Heerding MM et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Duke's stage B and C colorectal cancer. Br J Cancer 1997; 75(12): 1793-1801. (Pubitemid 27230706)
43. Mulcahy HE, Duffy MJ, Gibbons D et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344(8922): 583-584 (Pubitemid 24267218)
44. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes'B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14(7): 1026-1038. (Pubitemid 36950166)
45. Sier CF, Vloedgraven HJ, Ganesh S et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994; 107(5): 1449-1456. (Pubitemid 24328284)
46. Suzuki S, Hayashi Y, Wang Y et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 1998; 43(6): 798-805. (Pubitemid 28539659)
47. Ganesh S, Sier CF, Griffioen G et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54(15): 4065-4071. (Pubitemid 24258110)
48. Nekarda H, Siewert JR, Schmitt M et al. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343(8889): 117. (Pubitemid 24019365)
49. Zemzoum I, Kates RE, Ross JS et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21(6): 1022-1028. (Pubitemid 46594130)
50. Hildenbrand R, Schaaf A, Dorn-Beineke A et al. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009; 24(7): 869-877
51. Sakakibara T, Hibi K, Koike M et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005; 93(7): 799-803. (Pubitemid 41486440)
52. Ohba K, Miyata Y, Kanda S et al. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005; 174(2): 461-465. (Pubitemid 40981574)
53. Schmitt M, Wilhelm O, Reuning U et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinol Proteol 2000; 14: 114-132. (Pubitemid 30409285)
54. Pedersen H, Grøndahl-Hansen J, Francis D et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994, 54(1): 120-123. (Pubitemid 24042098)
55. Konecny G, Untch M, Pihan A et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001; 7(6): 1743-1749 (Pubitemid 32708644)
56. Waltz DA, Natkin LR, Fujita RM et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100(1): 58-67. (Pubitemid 27311243)
57. Deng C, Curriden SA, Wang S et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134(6): 1563-1571. (Pubitemid 26318027)
58. Grøndahl-Hansen J, Christensen IJ, RosenquisTC et al. High levels of urokinase-type plasminogen activator and its inhibitor RAM in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53(11): 2513-2521. (Pubitemid 23168015)
59. Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A et al. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study. Tumori 2011; 97(4): 532-539.
60. Knoop A, Andreasen PA, Andersen JA et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77(6): 932-940. (Pubitemid 28101782)
61. Ito H, Yonemura Y, Fujita H et al. Prognostic relevance of urokinase-type plasminogen actiator (uPA) and plasminogen activator inhibitor PAI-1 and PAI-2 in gastric cancer. Vlrchows Arch 1996; 427(5) 487-496. (Pubitemid 126828180)
62. Bouchet C, Spyratos F, Martin PM et al. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69(2): 398-405. (Pubitemid 24046572)
63. Maeda K, Chung YS, Sawada T et al. Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. Int J Oncol 1996; 8(3): 499-503. (Pubitemid 26082168)
64. Macaluso M, Montanari M, Marshall CM et al. Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells. Cell Death Differ 2006; 13(9): 1515-1522. (Pubitemid 44210354)
65. Darnell DA, Antalis TM, Johnstone RW et al. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 2003; 23(18): 6520-6532. (Pubitemid 37075763)
66. Sumiyoshi K, Serizawa K, Urano T et al. Plasminogen activator system in human breast cancer. Int J Cancer 1992; 50(3): 345-348.
67. Nagayama M, Sato A, Hayakawa H et al. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994; 73(5): 1398-1405. (Pubitemid 24072545)
68. Smith R, Xue A, Gill A et al. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 2007; 31 (3): 493-502. (Pubitemid 46356075)
69. Nordengren J, Fredstorp Lidebring M, Bendahl PO et al. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 2002; 97(3): 379-385.
70. Kammori M, Kaminishi M, Kobayashi K et al. Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report. Jpn J Clin Oncol 1999; 29(4): 187-191.
71. Minisini AM, Fabbro D, Di Loreto C et al. Markers of the uPA system and common prognostic factors in breast cancer. Am J Clin Pathol 2007; 128(1): 112-117. (Pubitemid 47121723)
72. Dublin E, Hanby A, Patel NK et al. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 2000; 157(4): 1219-1227.
73. Cai Z, Li YF, Liu FY et al. Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer. Ai Zheng 2007; 26(3): 312-317.
74. Horvatić Herceg G, Herceg D, Kralik M et al. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien Klin Wochenschr 2006; 118(19-20): 601-609. (Pubitemid 46118428)
75. Muracciole X, Romain S, Dufour H et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol 2002; 52(3): 592-598. (Pubitemid 34158718)
76. Itoh T, Hayashi Y, Kanamaru T et al. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15(4): 422-430. (Pubitemid 30262211)
77. Papadopoulou S, Scorilas A, Yotis J et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002; 23(3): 170-178. (Pubitemid 44858308)
78. Cozzi PJ, Wang J, Delprado W et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 2006; 37(11): 1442-1451. (Pubitemid 44584322)
79. Manders P, Tjan-Heijnen VC, Span PN et al. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 2004; 101(3): 486-494. (Pubitemid 38970599)
80. Herszényi L, Farinati F, Cardin R et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008; 10: 194.
81. Foekens JA, Look MR Peters HA et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87(10): 751-756.
82. Heiss MM, Allgayer H, Gruetzner KU et al. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997; 226(6): 736-745. (Pubitemid 28049650)
83. de Bruin PA, Verspaget HW, Griffioen G et al. Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis 1987; 1: 57-62. (Pubitemid 18066350)
84. de Bruin PA, Griffioen G, Verspaget HW et al. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987; 47(17): 4654-4657. (Pubitemid 17124643)
85. Mytnik M, Stasko J. D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C - role in prothrombotic state of colorectal cancer. Neoplasma 2011; 58(3): 235-238.
86. Halamkova J, Kiss I, Pavlovsky Z et al. Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients. Neoplasma 2011; 58(5): 377-385.
87. Seetoo DQ, Crowe PJ, Russell PJ et al. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82(3): 184-193. (Pubitemid 36278267)
88. Sato T, Nishimura G, Yonemura Y et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 1995; 52(4): 347-352.
89. Langenskiöld M, Holmdahl L, Angenete E et al. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009; 30(4): 210-220.
90. Leik CE, Su EJ, Nambi P et al. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006; 4(12): 2710-2715. (Pubitemid 44741569)